Literature DB >> 16691243

The SIRP family of receptors and immune regulation.

A Neil Barclay1, Marion H Brown.   

Abstract

The immune system must be highly regulated to obtain optimal immune responses for the elimination of pathogens without causing undue side effects. This tight regulation involves complex interactions between membrane proteins on leukocytes. Members of the signal-regulatory protein (SIRP) family, which are expressed mainly by myeloid cells, provide one example of these regulatory membrane proteins. There are three SIRP-family genes that encode proteins that have similar extracellular regions but different signalling potentials, and are therefore known as 'paired receptors'. In this Review, we describe recent studies defining the ligands of the SIRP-family members, with particular emphasis on relating the molecular interactions of these proteins to their role in immune-cell regulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691243     DOI: 10.1038/nri1859

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  166 in total

Review 1.  Macrophages as mediators of tumor immunosurveillance.

Authors:  Siddhartha Jaiswal; Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Trends Immunol       Date:  2010-05-07       Impact factor: 16.687

2.  The evolution of thrombospondins and their ligand-binding activities.

Authors:  Amber A Bentley; Josephine C Adams
Journal:  Mol Biol Evol       Date:  2010-04-28       Impact factor: 16.240

3.  CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation.

Authors:  Agueda Martínez-Barriocanal; Emma Comas-Casellas; Simo Schwartz; Margarita Martín; Joan Sayós
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

4.  Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; Max Jan; Rachel Weissman-Tsukamoto; Feifei Zhao; Christopher Y Park; Irving L Weissman; Ravindra Majeti
Journal:  Cancer Res       Date:  2010-12-21       Impact factor: 12.701

5.  Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.

Authors:  Mark P Chao; Siddhartha Jaiswal; Rachel Weissman-Tsukamoto; Ash A Alizadeh; Andrew J Gentles; Jens Volkmer; Kipp Weiskopf; Stephen B Willingham; Tal Raveh; Christopher Y Park; Ravindra Majeti; Irving L Weissman
Journal:  Sci Transl Med       Date:  2010-12-22       Impact factor: 17.956

6.  Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels.

Authors:  Richard K Tsai; Pia L Rodriguez; Dennis E Discher
Journal:  Blood Cells Mol Dis       Date:  2010-03-17       Impact factor: 3.039

Review 7.  CD47 in xenograft rejection and tolerance induction.

Authors:  Yong-Guang Yang
Journal:  Xenotransplantation       Date:  2010 Jul-Aug       Impact factor: 3.907

8.  Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells.

Authors:  Zhen Bian; Lei Shi; Ya-Lan Guo; Zhiyuan Lv; Cong Tang; Shuo Niu; Alexandra Tremblay; Mahathi Venkataramani; Courtney Culpepper; Limin Li; Zhen Zhou; Ahmed Mansour; Yongliang Zhang; Andrew Gewirtz; Koby Kidder; Ke Zen; Yuan Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-30       Impact factor: 11.205

9.  Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity.

Authors:  Qiong Liu; Wen Wen; Liang Tang; Chen-Jie Qin; Yan Lin; Hui-Lu Zhang; Han Wu; Charles Ashton; Hong-Ping Wu; Jin Ding; Wei Dong; Le-Xing Yu; Wen Yang; Dan-Dan Huang; Meng-Chao Wu; Hong-Yang Wang; He-Xin Yan
Journal:  Oncoimmunology       Date:  2016-08-23       Impact factor: 8.110

Review 10.  Recognition of additional roles for immunoglobulin domains in immune function.

Authors:  John P Cannon; Larry J Dishaw; Robert N Haire; Ronda T Litman; David A Ostrov; Gary W Litman
Journal:  Semin Immunol       Date:  2009-12-08       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.